Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationDepreciation & Amortization (IS)Long-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Savara (SVRA) Preferred Shares Issued (2011 - 2016)

Savara (SVRA) reported Preferred Shares Issued of $6000.0 for Q3 2016, down 99.97% on a QoQ basis from $22.5 million in Q1 2011.

Savara (SVRA) has 2 years of Preferred Shares Issued data on file, last reported at $6000.0 in Q3 2016.

  • Quarterly Preferred Shares Issued changed N/A year-over-year to $6000.0 in Q3 2016, while the trailing twelve-month figure through Dec 2016 was $22.5 million (changed N/A YoY) and the FY2016 annual result came in at $782000.0, down 91.09% from the prior year.
  • Preferred Shares Issued retreated to $6000.0 in Q3 2016 per SVRA's latest filing, from $22.5 million in the prior quarter.
  • Across five years, Preferred Shares Issued topped out at $6000.0 in Q3 2016 and bottomed at $6000.0 in Q3 2016.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Shares Issued (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Savara 1.30 Bn 1.30 Bn - -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2016 6,000.00
Sep 30, 2016 6,000.00
Mar 31, 2011 22.51 Mn
Mar 31, 2011 22.51 Mn